Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Photocure ASA ( (PHCUF) ) is now available.
Photocure ASA has announced progress in its collaboration with Richard Wolf to develop a new high-definition flexible blue light cystoscope for global commercialization. An interim solution, compatible with existing equipment, is now available, addressing an unmet need in bladder cancer diagnostics. This temporary setup allows urology centers to perform blue light flexible cystoscopy for patient surveillance, pending the arrival of the advanced HD scope. This development reinforces Photocure’s strategic market positioning and strengthens its partnership with Richard Wolf, aiming to enhance bladder cancer management.
More about Photocure ASA
Photocure ASA, known as The Bladder Cancer Company, operates in the healthcare industry with a focus on delivering transformative solutions for bladder cancer diagnosis and management. Their primary product involves a technology that enhances cancer cell visibility, improving patient outcomes. The company is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange.
YTD Price Performance: -2.72%
Average Trading Volume: 810
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $140.4M
For an in-depth examination of PHCUF stock, go to TipRanks’ Stock Analysis page.